A robust growth strategy is important for a fast developing specialty biopharmaceutical company. Through strategic in-licensing and productive academic collaborations, ObsEva is building a portfolio of products and product candidates for women’s reproductive health that can address significant unmet medical needs for millions of women worldwide.
In 2015, ObsEva entered into a collaboration agreement with Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company with approximately 70 years of expertise in the fields of obstetrics/gynecology, renal dialysis, urology, metabolism, and ophthalmology.
Under the terms of the agreement, ObsEva acquired the exclusive license to develop and commercialize Linzagolix worldwide (excluding certain Asian countries) for the treatment of uterine fibroids, endometriosis and other possible indications.
Should you represent a pharmaceutical company seeking a strong and committed partner for the development and the commercialization of a potential product, please do not hesitate to send an email to the contact below briefly describing your project.
We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.Continue to link
Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.Continue